Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Vericel
(NASDAQ:VCEL)
Intraday
$46.50
1.12
[2.47%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$46.50
1.12
[2.47%]
Last update: 3:24PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Vericel Stock (NASDAQ:VCEL)
Vericel Stock (NASDAQ: VCEL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 26, 2024
Analyst Scoreboard: 5 Ratings For Vericel
Benzinga Insights
-
Mar 26, 2024, 11:00AM
Truist Securities Reiterates Buy on Vericel, Maintains $54 Price Target
Benzinga Newsdesk
-
Mar 26, 2024, 9:15AM
Friday, March 01, 2024
A Closer Look at 4 Analyst Recommendations For Vericel
Benzinga Insights
-
Mar 1, 2024, 10:00AM
Truist Securities Maintains Buy on Vericel, Raises Price Target to $54
Benzinga Newsdesk
-
Mar 1, 2024, 8:44AM
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $53
Benzinga Newsdesk
-
Mar 1, 2024, 7:33AM
Thursday, February 29, 2024
Vericel Forecasts 2024 Revenue Of $237M-$241M Versus Consensus Of $240.24M, With Gross margin Of Approximately 70% And Adjusted EBITDA Margin Of Approximately 20%
Benzinga Newsdesk
-
Feb 29, 2024, 8:08AM
Vericel Q4 GAAP EPS $0.26 Beats $0.17 Estimate, Sales $65.00M Beat $63.93M Estimate
Benzinga Newsdesk
-
Feb 29, 2024, 7:56AM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Thursday, January 25, 2024
Truist Securities Upgrades Vericel to Buy, Raises Price Target to $51
Benzinga Newsdesk
-
Jan 25, 2024, 6:30AM
Tuesday, January 16, 2024
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Benzinga Insights
-
Jan 16, 2024, 12:00PM
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $46
Benzinga Newsdesk
-
Jan 16, 2024, 7:20AM
Tuesday, January 09, 2024
Vericel shares are trading higher after the company announced better-than-expected preliminary revenue for FY23 and Q4.
Benzinga Newsdesk
-
Jan 9, 2024, 11:51AM
Vericel FY23 Prelim. Total Net Revenue Expected To Be $197.5M vs $195.04M Est., Q4 Revenue Expected To Be ~$65M vs $62.6M Est.
Benzinga Newsdesk
-
Jan 9, 2024, 7:56AM
Thursday, December 28, 2023
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Shivani Kumaresan
-
Dec 28, 2023, 11:54AM
Thursday, November 09, 2023
Truist Securities Maintains Hold on Vericel, Raises Price Target to $39-Report released on 8th Nov 2023
Benzinga Newsdesk
-
Nov 9, 2023, 5:47PM
Truist Securities Maintains Hold on Vericel, Raises Price Target to $39
Benzinga Newsdesk
-
Nov 9, 2023, 4:50PM
Wednesday, November 08, 2023
Vericel Raises 2023 Revenue Guidance From $190M-$197M To $192.5M-$197.5M
Benzinga Newsdesk
-
Nov 8, 2023, 7:59AM
Vericel Q3 EPS $(0.08) Vs $(0.14) Last Year, Sales $45.58M Beat $45.15M Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 7:57AM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Monday, October 16, 2023
Analyst Ratings for Vericel
Benzinga Insights
-
Oct 16, 2023, 1:00PM
Leerink Partners Initiates Coverage On Vericel with Outperform Rating, Announces Price Target of $42
Benzinga Newsdesk
-
Oct 16, 2023, 12:00PM
Thursday, September 28, 2023
Vericel Announces Publication Of Results From Phase 3 Debride And Protect Study Of Thermal Burn Patients Treated With NexoBrid
Benzinga Newsdesk
-
Sep 28, 2023, 8:38AM
Thursday, September 21, 2023
Truist Securities Reiterates Hold on Vericel, Maintains $39 Price Target
Benzinga Newsdesk
-
Sep 21, 2023, 12:55PM
Stephens & Co. Reiterates Overweight on Vericel, Maintains $44 Price Target
Benzinga Newsdesk
-
Sep 21, 2023, 11:42AM
Analyst Ratings for Vericel
Benzinga Insights
-
Sep 21, 2023, 9:00AM
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $44.5
Benzinga Newsdesk
-
Sep 21, 2023, 8:22AM
Wednesday, September 20, 2023
Vericel Announces U.S. Commercial Availability Of NexoBrid For The Treatment Of Severe Thermal Burns In Adults
Happy Mohamed
-
Sep 20, 2023, 4:31PM
Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses
Vandana Singh
-
Sep 20, 2023, 12:04PM
Watching Vericel Corp.; J Capital Research Issues Short Report On Co
Benzinga Newsdesk
-
Sep 20, 2023, 10:36AM
Tuesday, August 29, 2023
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Faith Ashmore
-
Sponsored
Tuesday, August 08, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 11:00AM
BTIG Upgrades Vericel to Buy, Announces $39 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 6:44AM
Thursday, August 03, 2023
Expert Ratings for Vericel
Benzinga Insights
-
Aug 3, 2023, 5:00PM
Truist Securities Maintains Hold on Vericel, Lowers Price Target to $39
Benzinga Newsdesk
-
Aug 3, 2023, 12:17PM
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $41
Benzinga Newsdesk
-
Aug 3, 2023, 6:09AM
Wednesday, August 02, 2023
Earnings Scheduled For August 2, 2023
Benzinga Insights
-
Aug 2, 2023, 8:45AM
MediWound Said Partner Vericel Has Received The First Lot Of Nexobrid Finished Product From Mediwound For The U.S. Commercial Market In June 2023
Charles Gross
-
Aug 2, 2023, 8:04AM
Vericel Revises FY23 Revenue Guidence To $190M-$197M From $184M-$192M Vs $190.29M Est.
Happy Mohamed
-
Aug 2, 2023, 7:57AM
Vericel Q2 EPS $(0.11) Beats $(0.13) Estimate, Sales $45.92M Beat $42.81M Estimate
Happy Mohamed
-
Aug 2, 2023, 7:56AM
Wednesday, July 19, 2023
Truist Securities Maintains Hold on Vericel, Raises Price Target to $42
Benzinga Newsdesk
-
Jul 19, 2023, 9:58AM
Thursday, May 11, 2023
Truist Securities Maintains Hold on Vericel, Raises Price Target to $36
Benzinga Newsdesk
-
May 11, 2023, 7:50AM
Stephens & Co. Maintains Overweight on Vericel, Raises Price Target to $42
Benzinga Newsdesk
-
May 11, 2023, 7:10AM
Wednesday, May 10, 2023
Earnings Scheduled For May 10, 2023
Benzinga Insights
-
May 10, 2023, 9:12AM
Vericel: Q1 Earnings Insights
Benzinga Insights
-
May 10, 2023, 8:16AM
Vericel Raises FY23 Revenue Guidance To $184M-$192M vs $186.54M Est.
Benzinga Newsdesk
-
May 10, 2023, 7:57AM
Vericel Q1 EPS $(0.16) Misses $(0.15) Estimate, Sales $41.00M Beat $37.87M Estimate
Benzinga Newsdesk
-
May 10, 2023, 7:56AM
Tuesday, February 28, 2023
Vericel Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
Feb 28, 2023, 9:48AM
Monday, February 27, 2023
Analyst Expectations for Vericel's Future
Benzinga Insights
-
Feb 27, 2023, 1:01PM
Truist Securities Maintains Hold on Vericel, Raises Price Target to $31
Benzinga Newsdesk
-
Feb 27, 2023, 8:22AM
Thursday, February 23, 2023
Vericel Sees FY23 Revenue $180M-$188M Vs $192.58M Est
Happy Mohamed
-
Feb 23, 2023, 7:58AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch